Chordate Medical Holding (CMH.ST) Stock Analysis & AI Equity Report
Chordate Medical Holding (CMH.ST) overview
Chordate Medical Holding (CMH.ST) stock analysis and AI equity research. For the latest completed financial year, 2024, Chordate Medical Holding reported revenue of SEK 0.7m and operating profit of SEK -27.4m; the year-end share price was 8.98 SEK and market capitalisation was SEK 9.2m. Chordate Medical Holding is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Chordate Medical Holding's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-09-29. Data will be refreshed during report generation.
About Chordate Medical Holding
Chordate Medical Holding AB (publ) develops and commercializes Ozilia®, a CE-marked, drug-free neuromodulation treatment for chronic migraine and chronic rhinitis. The company sells its products through distributors to clinics and hospitals in selected markets in Europe, the Middle East and Israel. It has also announced and received approval for delisting from Nasdaq First North Growth Market.
Generate the Chordate Medical Holding report
Chordate Medical Holding is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Chordate Medical Holding and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.